Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Pyae Phyo

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 24, 2012
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malariaDebashish Das, Rupam Tripura, Aung Pyae Phyo, et al.
Plos One|February 24, 2009
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deploymentVerena Ilona Carrara, Julien Zwang, Elizabeth A Ashley, et al.
Plos Medicine|April 29, 2015
Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approachLisa J White, Jennifer A Flegg, Aung Pyae Phyo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2016
Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic FactorsAung Pyae Phyo, Elizabeth A Ashley, Tim J C Anderson, et al.
Plos One|August 7, 2010
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaNeena Valecha, Aung Pyae Phyo, Mayfong Mayxay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax MalariaCindy S Chu, Aung Pyae Phyo, Claudia Turner, et al.
Malaria Journal|November 15, 2013
Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivativesJennifer A Flegg, Philippe J Guérin, Francois Nosten, et al.
BMC Medicine|June 10, 2021
A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar borderMakoto Saito, Verena I Carrara, Mary Ellen Gilder, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax MalariaCindy S Chu, Aung Pyae Phyo, Khin Maung Lwin, et al.
Open Forum Infectious Diseases|January 16, 2026
<i>Plasmodium vivax</i> Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest ThailandCindy S Chu, Khin Maung Lwin, Kathy Burgoine, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 24, 2012
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malariaDebashish Das, Rupam Tripura, Aung Pyae Phyo, et al.
Plos One|February 24, 2009
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deploymentVerena Ilona Carrara, Julien Zwang, Elizabeth A Ashley, et al.
Plos Medicine|April 29, 2015
Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approachLisa J White, Jennifer A Flegg, Aung Pyae Phyo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2016
Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic FactorsAung Pyae Phyo, Elizabeth A Ashley, Tim J C Anderson, et al.
Plos One|August 7, 2010
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaNeena Valecha, Aung Pyae Phyo, Mayfong Mayxay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax MalariaCindy S Chu, Aung Pyae Phyo, Claudia Turner, et al.
Malaria Journal|November 15, 2013
Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivativesJennifer A Flegg, Philippe J Guérin, Francois Nosten, et al.
BMC Medicine|June 10, 2021
A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar borderMakoto Saito, Verena I Carrara, Mary Ellen Gilder, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax MalariaCindy S Chu, Aung Pyae Phyo, Khin Maung Lwin, et al.
Open Forum Infectious Diseases|January 16, 2026
<i>Plasmodium vivax</i> Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest ThailandCindy S Chu, Khin Maung Lwin, Kathy Burgoine, et al.
Pageof 10